Effects of Transcranial Direct Current Stimulation (tDCS) and Transcranial Ultrasound on Osteoarthritis Pain of the Knee
1 other identifier
interventional
38
1 country
1
Brief Summary
The purpose of this study is to see the effects of transcranial direct current stimulation (tDCS) on the pain associated with osteoarthritis of the knee. The investigators hypothesize that there will be a decrease in pain levels with active stimulation, when compared to sham stimulation. Before, during and after stimulation, the investigators will measure and assess changes intracranial blood flow with transcranial ultrasound.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable chronic-pain
Started Jan 2011
Longer than P75 for not_applicable chronic-pain
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2011
CompletedFirst Submitted
Initial submission to the registry
June 29, 2011
CompletedFirst Posted
Study publicly available on registry
July 27, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 30, 2014
CompletedStudy Completion
Last participant's last visit for all outcomes
July 30, 2014
CompletedApril 24, 2020
April 1, 2020
3.6 years
June 29, 2011
April 23, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Changes in pain scale
Determine whether anodal transcranial direct current stimulation in conjunction with transcranial ultrasound (applied in a diagnostic mode) is effective in reducing pain in subjects with chronic osteoarthritis pain, as measured by changes in the Visual Analogue Scale (VAS) for pain. VAS will be measured immediately before the tDCS stimulation sessions, and immediately after the tDCS stimulation sessions for the subject's duration in the trial. VAS will also be measured at baseline, and at three follow-up sessions after tDCS stimulation (up to 2 months after tDCS stimulation)
Measured for approximately 2 months
Secondary Outcomes (2)
Changes in cutaneous allodynia/hyperalgesia
Measured for approximately 2 months
Assessment of hemodynamic changes with transcranial ultrasound
Measured for approximately 2 months
Study Arms (2)
Active tDCS + transcranial ultrasound
EXPERIMENTALSubjects will undergo 20 minutes active tDCS in conjunction with transcranial ultrasound measurements.
Sham tDCS + transcranial ultrasound
SHAM COMPARATORSubjects will receive sham tDCS in conjunction with transcranial ultrasound measurements.
Interventions
Subjects will be randomized to undergo either 5 sessions of active tDCS stimulation, or 5 sessions of sham tDCS stimulation. For both active and sham stimulation, we will use electrodes of 35cm\^2 and an intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. Active stimulation will last for 20 minutes, while sham stimulation will only last for 30 seconds, mimicking the sensations during active stimulation.
Eligibility Criteria
You may qualify if:
- Providing informed consent to participate in the study
- to 64 years old
- Having chronic osteoarthritis knee pain in either knee (existing pain for more than 6 months with an average of at least 3 on a 0-10 VAS scale)
- Pain resistant to common analgesics and medications for chronic pain such as Tylenol, Aspirin, Ibuprofen, Soma, Parafon Forte DCS, Zanaflex, and Codeine.
- Must have the ability to feel pain as self reported
You may not qualify if:
- Subject is pregnant.
- Contraindications to tDCS:
- metal in the head
- implanted brain medical devices
- Contraindications to TUS:
- metal in the head
- implanted brain medical devices
- History of alcohol or drug abuse within the past 6 months as self reported
- Use of carbamazepine within the past 6 months as self reported.
- Suffering from severe depression (with a score of \>30 in the Beck Depression Inventory)
- History of neurological disorders as self reported.
- History of unexplained fainting spells as self reported,
- History of head injury resulting in more than a momentary loss of consciousness as self reported
- History of neurosurgery as self reported
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Spaulding Rehabilitation Hospitallead
- Highland Instruments, Inc.collaborator
Study Sites (1)
Spaulding Rehabilitation Hospital
Boston, Massachusetts, 02114, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Felipe Fregni, MD, PhD, MPH
Spaulding Rehabilitation Hospital (SRH)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
June 29, 2011
First Posted
July 27, 2011
Study Start
January 1, 2011
Primary Completion
July 30, 2014
Study Completion
July 30, 2014
Last Updated
April 24, 2020
Record last verified: 2020-04